Metabolomic study of biochemical changes in the plasma and urine of primary dysmenorrhea patients using UPLC-MS coupled with a pattern recognition approach

Journal of Proteome Research

Volumn 12, Issue 2, 2013, Pages 852-865

  Su, Shulan ^a   Duan, Jinao ^a   Wang, Peijuan ^b   Liu, Pei ^a   Guo, Jianming ^a   Shang, Erxin ^a   Qian, Dawei ^a   Tang, Yuping ^a   Tang, Zongxiang ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine   (China)

Author keywords

metabolomics; potential biomarkers; primary dysmenorrhea (PD); Shaofu Zhuyu formula concentrated granule (SFZYFG); UPLC QTOF MS MS

Indexed keywords

GLYCEROPHOSPHOLIPID; SPHINGOLIPID; STEROID HORMONE;

ARTICLE; AUTOMATED PATTERN RECOGNITION; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; DYSMENORRHEA; FEMALE; HORMONE METABOLISM; HUMAN; METABOLOMICS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEROID METABOLISM; SYNTHESIS; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUGS, CHINESE HERBAL; DYSMENORRHEA; FEMALE; GLYCEROPHOSPHOLIPIDS; GONADAL STEROID HORMONES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; PRINCIPAL COMPONENT ANALYSIS; PROSPECTIVE STUDIES; SPHINGOLIPIDS; TANDEM MASS SPECTROMETRY;

EID: 84873330197     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300935x     Document Type: Article

References (43)

1. French, L. Dysmenorrhea Am. Fam. Physician 2005, 71 (2) 285-291
2. Davis, A. R.; Westhoff, C. L. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives J. Pediatr. Adolesc. Gynecol. 2001, 14 (1) 3-8
3. Chan, W. Y.; Dawood, M. Y. Prostaglandin levels in menstrual fluid of non dysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or Ibuprofen therapy Adv. Prostaglandin Thromboxane Res. 1980, 8, 1443-1447
4. 2α receptors and their profiles during pathological states J. Clin. Endocr. Metab. 1983, 57 (2) 360-366
5. Harel, Z. A. Contemporary approach to dysmenorrhea in adolescents Paediatr. Drugs 2002, 4 (12) 797-805
6. Valentin, L.; Sladkevicius, P.; Kindahl, H.; Broeders, A.; Marsal, K.; Melin, P. Effects of a vasopressin antagonist in women with dysmenorrhea Gynecol. Obst. Invest. 2000, 50 (3) 170-177
7. Knobil, E. The neuroendocrine control of the menstrual cycle Recent Prog. Horm. Res. 1980, 36, 53-88
8. Dawood, M. Y. Primary dysmenorrhea advances in pathogenesis and management Obst. Gynecol. 2006, 108 (2) 428-441
9. Zahradnik, H. P.; Hanjalic-Beck, A.; Groth, K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review Contraception 2010, 81 (3) 185-196
10. Marjoribanks, J.; Proctor, M. L.; Farquhar, C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea Cochrane Database Syst. Rev. 2003, 4 CD001751
11. Davis, A. R.; Westhoff, C.; O'Connell, K.; Gallagher, N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial Obstet. Gynecol. 2005, 106 (1) 97-104
12. Dawood, M. Y. Hormones, prostaglandin and dysmenorrhea. In Dysmenorrhea; Dawood, M. Y., Ed.; Williams and Wilkins: Baltimore, MD, 1981; pp 20-52.
13. Proctor, M. L.; Roberts, H.; Farquhar, C. M. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea Cochrane Database Syst. Rev. 2001, 4 CD002120
14. Johansen, K. K.; Wang, L.; Aasly, J. O.; White, L. R.; Matson, W. R.; Henchcliffe, C.; Beal, M,F.; Bogdanov, M. Metabolomic profiling in LRRK2-related Parkinson's disease PloS One 2009, 4 (10) e7551
15. Nicholson, J. K.; Wilson, I. D. Opinion: understanding global systems biology: metabonomics and the continuum of metabolism Nat. Rev. Drug Discovery 2003, 2 (8) 668-676
16. Sun, L. Y.; Hu, W. H.; Liu, Q.; Hao, Q. F.; Mao, S.; Sun, B.; Zhang, Q.; Mao, S.; Qiao, J.; Yan, X. Z. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients J. Proteome Res. 2012, 11 (5) 2937-2946
17. Wang, X. J.; Yang, B.; Zhang, A. H.; Sun, H.; Yan, G. L. Potential drug targets on insomnia and intervention effects of jujuboside A through metabolic pathway analysis as revealed by UPLC/ESI-SYNAPT-HDMS coupled with pattern recognition approach J. Proteomics 2012, 75 (4) 1411-1427
18. Vinaixa, M.; Rodriguez, M. A.; Samino, S.; Díaz, M.; Beltran, A.; Mallol, R.; Bladé, C.; Ibañez, L.; Correig, X.; Yanes, O. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin Polytherapy PLoS One 2011, 6 (12) e29052
19. Tan, G. G.; Liao, W. T.; Dong, X.; Yang, G. J.; Zhu, Z. Y.; Li, W.; Chai, Y.; Lou, Z. Metabonomic profiles delineate the effect of traditional Chinese medicine Sini decoction on myocardial infarction in rats PLoS One 2012, 7 (4) e34157
20. Zhang, A. H.; Sun, H.; Wang, P.; Han, Y.; Wang, X. J. Recent and potential developments of biofluid analyses in metabolomics J. Proteomics 2012, 75 (4) 1079-1088
21. Jansson, J.; Willing, B.; Lucio, M.; Fekete, A.; Dicksved, J.; Halfvarson, J.; Tysk, C.; Schmitt-Kopplin, P. Metabolomics reveals metabolic biomarkers of Crohn's disease PLoS One 2009, 4 (7) e6386
22. Fan, M. Clinical observation of Shaofu Zhuyu decotiong for treating primary dysmenorrhea of cold coagulation and blood stasis Beijing J. Trad. Chin. Med. 2011, 30 (2) 455-456
23. Cheng, Q. Q.; Zhu, Y. Clinical study on primary dysmenorrheal of blood-stasis of cold-coagulation syndrome treated with modified Shaofu Zhuyu decoction J. Chin. Med. 2011, 16 (4) 1249-1250
24. Su, S. L.; Guo, J. M.; Duan, J. A.; Wang, T. J.; Qian, D. W.; Shang, E. X.; Tang, Y. P. Ultra-performance liquid chromatography-tandem mass spectrometry analysis of the bioactive components and their metabolites of Shaofu Zhuyu decoction active extract in rat plasma J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2010, 878 (3-4) 355-362
25. Su, S. L.; Hua, Y. Q.; Duan, J. A.; Zhou, W.; Shang, E. X.; Tang, Y. P. Inhibitory effects of active fraction and its main components of Shaofu Zhuyu decoction on uterus contraction Am. J. Chin. Med. 2010, 38 (4) 777-787
26. Su, S. L.; Hua, Y. Q.; Duan, J. A.; Shang, E. X.; Tang, Y. P.; Bao, X. J.; Lu, Y.; Ding, A. W. Hypothesis of active components in volatile oil from a Chinese herbs formulation, 'Shao-Fu-Zhu-Yu Decoction', using GC-MS and chemometrics J. Sep. Sci. 2008, 31 (6) 1085-1091
27. Proctor, M.; Farquhar, C. Diagnosis and management of dysmenorrhoea Br. Med. J., Clin. Res. 2006, 332 (7550) 1134-1138
28. Lenz, E. M.; Wilson, I. D. Analytical strategies in metabonomics J. Proteome Res. 2007, 6 (2) 443-458
29. Tu, C. H.; Niddam, D. M.; Chao, H. T.; Liu, R. S.; Hwang, R. J.; Yeh, T. C.; Hsieh, J. C. Abnormal cerebral metabolism during menstrual pain in primary dysmenorrheal NeuroImage 2009, 47 (1) 28-35
30. Patti, G. J.; Yanes, O.; Shriver, L. P.; Courade, J. P.; Tautenhahn, R.; Manchester, M.; Siuzdak, G. Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin Nat. Chem. Biol. 2012, 8 (3) 232-234
31. Watterson, K.; Sankala, H.; Milstien, S.; Spieqel, S. Pleiotropic actions of sphingosine-1-phosphate Prog. Lipid Res. 2003, 42 (4) 344-357
32. Marsh, E. E.; Shaw, N. D.; Klingman, K. M.; Tiamfook-Morgan, T. O.; Yialamas, M. A.; Sluss, P. M.; Hall, J. E. Estrogen levels are higher across the menstrual cycle in African-American women compared with Caucasian women J. Clin. Endocrinol. Metab. 2011, 96 (10) 3199-3206
33. Cornel, K. M.; Kruitwagen, R. F.; Delvoux, B.; Visconti, L.; Van de Vijver, K. K.; Day, J. M.; Van Gorp, T.; Hermans, R. J.; Dunselman, G. A.; Romano, A. Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol J. Clin. Endocrinol. Metab. 2012, 97 (4) E591-E601
34. Arulkumaran, S.; Kandola, M. K.; Hoffman, B.; Hanyaloglu, A. C.; Johnson, M. R.; Bennett, P. R. The roles of prostaglandin EP 1 and 3 receptors in the control of human myometrial contractility J. Clin. Endocrinol. Metab. 2012, 97 (2) 489-498
35. Li, S.; Zhang, Z. Q.; Wu, L. J.; Zhang, X. G.; Li, Y. D.; Wang, Y. Y. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network IET Syst. Biol. 2007, 1 (1) 51-60
36. Ma, T.; Tan, C.; Zhang, H.; Wang, M.; Ding, W.; Li, S. Bridging the gap between traditional Chinese medicine and systems biology: the connection of cold syndrome and NEI network Mol. BioSyst. 2010, 6 (4) 613-619
37. Wymann, M. P.; Schneiter, R. Lipid signalling in disease Nat. Rev. Mol. Cell Biol. 2008, 9 (2) 162-176
38. Ye, X.; Chun, J. Lysophosphatidic acid (LPA) signaling in vertebrate reproduction Trends Endocrinol. Metab. 2010, 21 (1) 17-24
39. Schumacher, M.; Guennoun, R.; Ghoumari, A.; Massaad, C.; Robert, F.; El-Etr, M.; Akwa, Y.; Rajkowski, K.; Baulieu, E. E. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system Endocr. Rev. 2007, 28 (4) 387-439
40. Marinello, E.; Riario-Sforza, G.; Marcolongo, R. Plasma follicle- stimulating hormone, luteinizing hormone, and sex hormones in patients with gout Arthritis Rheum. 1985, 28 (2) 127-131
41. 2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease J. Clin. Endocrin. Metab. 2005, 90 (5) 3100-31005
42. 2α production in endometrial epithelial cells by inhibiting COX-2 expression and activity Phytomedicine 2008, 15 (12) 1046-1052
43. Su, S. L.; Duan, J. A.; Wang, T. J.; Yu, L.; Hua, Y. Q.; Tang, Y. P. Shaofu Zhuyu decoction on hemorheology and ovarian function in rat model of Han-Ning blood stasis Chin. J. Exper. Trad. Med. Form. 2008, 14 (12) 14-16